A Bold Vision for the Future: Aiming to Restore Sight Through Groundbreaking Eye Transplants
The race to conquer blindness has entered a thrilling new phase, fueled by an audacious initiative from the Advanced Research Projects Agency for Health (ARPA-H). Four teams nationwide, including one led by the CU Anschutz Medical Campus, will receive a combined $125 million to pursue a potentially revolutionary goal: the first-ever vision-restoring eye transplant.
Dr. Kia Washington, the lead researcher for the CU Anschutz team, expressed profound optimism for the project. “This is no easy undertaking,” she stated, “but I believe we can achieve this together, and I’ve never been more hopeful that a cure for blindness is within reach.”
This ambitious national effort, likened by many to the historic Apollo moon landing, will rely on a multi-pronged approach.
The CU team, one of four awarded funding by ARPA-H, will focus on developing functional eye transplants utilizing cutting-edge stem cell and bioelectronic technologies. Their research will involve collaborations with specialists at institutions across the country, creating a national network of expertise.
"Taking multiple shots on goal" is essential, according to Dr. Calvin Roberts, overseeing the project for ARPA-H, to ensure progress in overcoming this monumental scientific challenge.
Dr. Daniel Pelaez, lead investigator for the University of Miami’s Bascom Palmer Eye Institute, another ARPA-H funded team, emphasized the profound implications of such a breakthrough. “If researchers can successfully transplant the human eye and restore vision,” he said, "it might help unlock deeper discoveries about repairing damage to the brain and spine, as well as addressing hearing loss."
He highlighted the unique challenge posed by the eye, along with the inner ear, brain, and spinal cord, as the only organ systems yet to be successfully transplanted. These organs belong to the central nervous system, which has a limited capacity for self-repair.
Two key hurdles stand in the way of success: perfecting the removal and preservation of donor eyes and successfully connecting and repairing the delicate optical nerve, which transmits visual information from the eye to the brain.
A milestone was reached in November 2023 when a team at NYU Langone Health performed the world’s first full eye transplant as part of a partial face transplant. While a remarkable achievement, this procedure did not restore vision to the patient.
Dr. Washington’s team has already demonstrated success transplanting eyes in rats, albeit without restoring vision. Their next steps involve replicating this in larger animals, focusing on refining optic nerve regeneration strategies and minimizing the risk of donor organ rejection.
Pelaez’s team has successfully perfected eye removal in cadavers and studied regeneration processes in animals like salamanders and zebrafish, which possess impressive regenerative abilities. Their research will also focus on developing a "life-support" machine to ensure the viability of donor eyes during the removal process.
A third team, InGel Therapeutics, a Massachusetts-based Harvard spinoff, will explore the potential of 3D-printed technology and micro-tunneled scaffolds to facilitate optic nerve regeneration and repair.
<>
The vast scope of this endeavor necessitates both collaboration and competition.The teams will share their findings while striving to develop the most effective treatment strategies.
U.S. Representative Diana DeGette, a strong advocate for medical advancement, reaffirmed her commitment to preserving this crucial research funding, even amid political transitions.
With the launch of these groundbreaking projects, researchers are embarking on a journey as ambitious as the moon landing. As Dr. Washington proclaimed, “We have launched, and we are on our trajectory.”
